CSL Share Price
View CSL's share price performance over a 12 month period.
Latest Financial ReportsCSL Profile on ASX website
Computershare's Investor Centre website
Financial Calendar 2013
13 Feb -
14 Aug -
Questions about my Shareholding
Please call CSL's share registry ComputerShare on 1800 646 882 for queries regarding address changes, dividend payments, etc.
About the CSL Group
CSL Limited News
CSL Behring News
Head of Investor Relations
Phone: +613 9389 2818
Subscribe to News Alert
To receive the latest updates about CSL, sign up for our email
CSL Limited has over 10,000 staff in more than 20 countries. We produce many life-saving and life-enhancing medicines that enable thousands of people around the world to lead normal healthy lives. Our headquarters is in Australia and we have substantial manufacturing operations in the US, Germany and Switzerland.
CSL is a global specialty biopharmaceutical company that researches, develops, manufactures and markets biotherapies to treat and prevent a range of human medical conditions. We produce safe and effective therapies for patients who rely on them for their quality of life, and sometimes for life itself.
Half Year Results announcement for 2012/13
CSL Limited (ASX:CSL) today announced a net profit after tax of US$627 million for the six months ended 31 December 2012, up US$123 million or 24% on a reported basis when compared to the prior comparable period (PCP). Earnings per share grew 30%, benefiting from current and past capital management initiatives.
Change to 2013 Dividend Payment Dates
CSL Limited (ASX:CSL) is pleased to announce that, in line with its previous announcement on 17 December 2012 to bring forward the announcement of its Half Year and Full Year Results Announcements by one week, it will also bring forward the payment date of its interim and full year dividends by one week.
CSL Lifts Profit Guidance
CSL Limited (ASX:CSL) today announced a revised US Dollar profit outlook for fiscal 2013. The Company now expects net profit after tax to grow by approximately 20% at constant currency1
, despite competitive business conditions.
Prior ASX Releases
View the ASX Archive